Lawyers predict Biosecure passage in lame duck session, but Senate may decide key details

BETHESDA, MD — A panel of DC-focused lawyers predicted that the anti-China Biosecure Act is likely headed for final passage during the congressional “lame duck” period …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ionis outlines Phase 3 data for rare disease drug, preps for another potential launch

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 1, 2024

Revolutionizing hepatocyte count for researchers

In this interview, NewsMedical speaks to DeNovix’s Dan Schieffer about the new app developed for CellDrop, and how it aims to revolutionize hepatocyte count for

April 3, 2024

Cannabis Company Q4 Financials Were Not Exciting

The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. This update is our first since

March 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.